The partner network reflects the expertise necessary to ensure optimal project development and exit.
Former Senior Vice President Finance & Business Administration of Pharmacia Consumer Healthcare. Chairman of Adenovir Pharma AB. Former chairman of Ambria Dermatology AB and board member of LIDDS AB.
B.Sc. (Econ), J.D, LL.M, Executive Chairman of NeuroVive Pharmaceutical AB (publ). Advisor to pharmaceutical, biotech, medical device and other high technology companies. Former project leader of DuoCort AB and AcuCort AB. Innovator in Laccure AB and Trophea AB.
Professor of Endocrinology, Sahlgrenska Academy, University of Gothenburg and previous Head of Department of Internal Medicine, Sahlgrenska University Hospital. Co-founder of biotech company Tercica CA, US. Chairman of Oncorena Holding AB. Board member of AcuCort AB.
PhD, former Senior Vice President Corporate Development at Biovitrum and Vice President Global Licensing at Pharmacia. Board member of AcuCort AB, Adenovir Pharma AB and Laccure AB.
Robert JM Brummer
MD, PhD, Professor of Gastroenterology and Clinical Nutrition, Director Nutrition-Gut-Brain Interactions Research Center. Pro-Vice-Chancellor Internationalisation, External Relations and Innovation at Örebro University since 2016. Engagement in several national and international board/expert/review functions within the domain of gastrointestinal and nutritional sciences, agro-food and nutritional innovation. Chairman of the Board of Örebro University Holding AB and representative of Örebro University in a number of national and international organisations.
PhD, Professor in Bioorganic Chemistry at Lund Institute of Technology at Lund University. The research is focused towards the use of small sugar molecules in anti-tumor treatment as well as physical-organic aspects of carbohydrates. Past and present innovator and board member in startup companies. Author of textbooks in Organic Chemistry. Key contributor to Adenovir Pharma AB.
MD, PhD, Professor at the Department of Dermatology at Sahlgrenska Academy, University of Gothenburg. World leading researcher in dermatology with a special interest in Mycology and Dermato-Pharmacology. Innovator and former board member of Ambria Dermatology AB and innovator in Trophea AB.
Attorney-at-Law, European Patent Attorney, European Trademark and Design Attorney. Founder and former CEO and senior advisor of Ström & Gulliksson AB, founder board member and Senior Partner of Advokatbyrån Gulliksson, Partner and Member of the Board of Arator Group, Past President of Licensing Executives Society International (LESI) and LES Scandinavia. Former board member of P.U.L.S. AB and Ambria Dermatology AB.
MD, PhD (Medicine and Economics), Professor in Clinical Pharmacology at the Department of Medicine, Sahlgrenska Academy, University of Gothenburg. Leading researcher in Cardiovascular Medicine. Head of the biomedical entrepreneurship program at the University of Gothenburg. Author of more than 400 scientific publications. Innovator in multiple PULS project companies.
MD, PhD, Professor emeritus of Endocrinology at Sahlgrenska Academy, University of Gothenburg. Chairman of InternetMedicin AB, board member of Havsfrun Investment AB and several other companies.
MD, PhD, Professor of Cardiothoracic Surgery at the Institute of Medicine, Sahlgrenska Academy, University of Gothenburg. Research interest in extracorporeal circulation, inflammation and coagulation. Author or co-author of more than 60 scientific papers.
MD, PhD, Professor of Endocrinology, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg. Editor of the European Journal of Endocrinology, secretary of the Growth Hormone Research Society. Board member of Trophea AB. Innovator of DuoCort Pharma AB and Trophea AB.
Former CEO of Pharmacia Consumer Healthcare worldwide, Senior Vice President of Pharmacia Corporation, member of Pharmacia’s executive management group from 1995-2000. Founder of P.U.L.S. AB. Board member of P.U.L.S. AB and Laccure AB. Innovator in multiple PULS project companies.
M.Sc. (Pharm.) Solid experience from international marketing and drug development/clinical research. Leadership positions within Pharmacia, among others as Vice President and Business Manager for growth hormone. Former chairman of Jederstrom Pharmaceuticals. Co-founder of TKT-Europe-5S. Board member of Pulsetten AB and Glactone Pharma AB.
M.Sc. (Pharm). CEO of GMP consulting company, TQ Kvalitetskonsult AB. Co-founder and CEO of QP Support AB. Licensed Qualified Person with focus on quality systems and auditing according to cGMP in both the EU and the US. Co-founder of Dilafor AB. Board member of AcuCort AB and Trophea AB.
LL.M, Senior Partner in the human venture capital company Lavindia AB. General Counsel experiences of Pharmacia Group, Active Biotech AB and SBL Vaccin AB and other extensive experience from various senior positions. Chairman of Trophea, board member of Adenovir Pharma AB, Cebix Sweden AB, Jatab Care AB, Scandinavian Biopharma Holding AB, Synphora AB and Lavindia AB.
PhD, Associate Professor in Physiology, Lund University. Head Pipeline Sourcing Senior Director, LEO Pharma A/S. Former Director Strategic Planning and Business Development at AstraZeneca, several senior leadership positions at Pharmacia, Medical Director at Perstorp Pharma and Head of Preclinical R&D at Gambro. Board of Director of Genovis. Board member of Oncorena Holding AB.
MD, PhD, Professor at the Department of Internal Medicine, Sahlgrenska Academy, University of Gothenburg. Internationally recognized and award winning researcher in metabolic bone diseases and innovator in Trophea AB. Former chairman of P.U.L.S. AB.
MD, PhD, Professor of Oncology, Department of Oncology, Clinical Sciences, Lund University. Research interest in cancer epidemiology, cancer genetics, tumour biology, cancer prognosis and therapy. Published more than 500 scientific papers. Board member of Oncorena Holding AB.
Market economist. Runnberg has held senior executive positions in several international medtech companies including Gambro and HemoCue in Sweden; Diatek Medical Technologies, Block Medical and HemoCue, Inc. in California, USA and Vidacare B.V. in the Netherlands. Presently he is an industrial advisor to the Swedish private equity fund Valedo, engaged in the Clinical Innovation Fellowships program at KTH, Stockholm and a board member at Medicon Bridge in Lund. Former chairman of P.U.L.S. AB.
DVM, PhD, former consulting professor in Experimental Obstetrics and Gynecology at Uppsala University, Associate Professor in Pharmacology at the Veterinary Faculty of SLU (Swedish University of Agricultural Sciences). Former research director at Pharmacia, Perstorp and Novo Nordisk. Innovator in Laccure AB.
M.Sc, PhD, Professor in Organic Chemistry, Dean at Faculty of Science, Lund University. Major research fields are biologically active secondary metabolites and medicinal chemistry. Author or co-author of more than 330 publications in scientific journals, 20 patents/patent applications, and 5 text books in organic chemistry/chemical toxicology. Board member of P.U.L.S. AB and Glactone Pharma AB. Innovator in multiple PULS project companies.
B.Sc. Econ. Former VP IMS Health Europe, MD IMS Health UK, VP Pharmacia&Upjohn Europe, MD KabiPharmacia UK, President KabiVitrum International. Board member of Stockholm Corporate Finance AB, Comtax AB, WntResearch AB and Vicore Pharma Holding AB. Former board member of LIDDS AB.
MD, PhD, CEO of Oncorena. Former global Vice President Strategy, AstraZeneca Oncology & Infection. Professor, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg. CEO of Innoext AB. Board Director of Diaprost AB and Stayble Therapeutics AB. Chairman of Glactone Pharma AB and LIDDS AB. Innovator in Trophea AB.
M.Sc., extensive senior experience of pharmaceutical research and development. Most recently as Global Head and Vice President Clinical Development within AstraZeneca and before that as Global Head and Vice President Pharmaceutical and Analytical R&D, AstraZeneca. Presently board member and advisor in life science. Board member of P.U.L.S. and Adenovir Pharma AB.